JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib

OBJECTIVE: Janus kinase inhibitors (JAKinibs) are efficacious in rheumatoid arthritis (RA) with variable reported rates of adverse events, potentially related to differential JAK family member selectivity. Filgotinib was compared with baricitinib, tofacitinib and upadacitinib to elucidate the pharma...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ann Rheum Dis
Main Authors: Traves, Paqui G, Murray, Bernard, Campigotto, Federico, Galien, René, Meng, Amy, Di Paolo, Julie A
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2021
Teme:
Rheumatoid Arthritis
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8237188/
https://ncbi.nlm.nih.gov/pubmed/33741556
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2020-219012
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki